847818-49-9

Usage

Uses

Used in Medicinal Chemistry:
4-bromo-1-(2-methoxyethyl)-1H-pyrazole is used as a valuable scaffold for the design and synthesis of novel pharmaceuticals due to its molecular structure and properties.
Used in Drug Development:
4-bromo-1-(2-methoxyethyl)-1H-pyrazole is used in the development of drugs targeting a variety of biological pathways, making it a promising candidate for various applications in the pharmaceutical industry.
Used in Other Industrial Processes:
4-bromo-1-(2-methoxyethyl)-1H-pyrazole may also have uses in other industrial processes, although specific applications have not been detailed in the provided materials. Researchers continue to explore its potential uses and properties in various applications.

Upstream product

• 2075-45-8 4-bromo-1H-pyrazole 
• 6482-24-2 2-Bromoethyl methyl ether 
• 627-42-9 2-chloroethyl methyl ether 

Downstream Products

• 847818-71-7 1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 
• 847818-59-1 1-(2-methoxyethyl)-1H-pyrazol-4-ylboronic acid 

Relevant academic research and scientific papers

CDK8/19 INHIBITORS

The present invention relates to novel compounds of formula I: which have the properties of CDK8/19 inhibitors, to a pharmaceutical composition comprising said compounds, and to use thereof as a medicine for treating diseases and disorders.

CONDENSED-CYCLIC COMPOUND

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

Pyrazole N-alkylation method

The invention provides a pyrazole N-alkylation method. Pyrazole or pyrazole derivatives and alkyl halogenated hydrocarbons react in a solvent under the existence of quaternary ammonium salt catalysts;N-alkyl substituted pyrazole is obtained. The method provided by the invention has the advantages that the operation is simple; the cost is low; the anhydrous oxygen-free environment is not needed; heating is not needed; the yield is high; the amplified industrialized production can be easily realized.

KINASE INHIBITOR COMPOUNDS

Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

Synthesis of pinacol esters of 1-alkyl-1H-pyrazol-5-yl- and 1-alkyl-1H-pyrazol-4-ylboronic acids

Starting from 1H-pyrazol, a wide number of 1-alkyl-1H-pyrazol-4-yl and 1-alkyl-1H-pyrazol-5-ylboronic acids and their pinacol esters were synthesized and characterized. The key step in the described methodology is the regioselective lithiation of the pyrazole ring. The synthesized pinacolates are stable under prolonged storage and can be used as convenient reagents in organic synthesis.